Peter Eu

4.3k citations

55 papers · 3.1k indexed · 2 hit papers · h-index 26

Impact in

Radiology, Nuclear Medicine and Imaging top 0.5%
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
Pulmonary and Respiratory Medicine top 1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment

Papers in ⓘ

Radiology, Nuclear Medicine and Imaging 35
- Radiopharmaceutical Chemistry and Applications 24
- Medical Imaging Techniques and Applications 13
Pulmonary and Respiratory Medicine 26
- Prostate Cancer Treatment and Research 14
- Lung Cancer Diagnosis and Treatment 5

Co-authors: Rodney J. Hicks (32 shared papers)Michael S. Hofman (24 shared papers)Grace Kong (9 shared papers)Price Jackson (6 shared papers)Amir Iravani (9 shared papers)Tim Akhurst (5 shared papers)Scott Williams (5 shared papers)Declan G. Murphy (4 shared papers)
Journals: Journal of Nuclear Medicine (9 papers)European Journal of Nuclear Medicine and Molecular Imaging (9 papers)Journal of Clinical Oncology (4 papers)Cancer Imaging (2 papers)Scientific Reports (1 paper)
Partner nations: Australia United States Canada

In The Last Decade

Peter Eu

55 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study 2018 · 815 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 The Lancet Oncology
2018 Journal of Nuclear Medicine

Peers

Countries citing papers authored by Peter Eu

Since Specialization

Citations

This map shows the geographic impact of Peter Eu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Eu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Eu more than expected).

Fields of papers citing papers by Peter Eu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Eu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Eu. The network helps show where Peter Eu may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Eu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Eu Line = papers co-authored together Peter Eu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study The Lancet Oncology ·Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G. Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott Williams, Shahneen Sandhu Hit paper breakdown →	2018	815
2	Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes Journal of Nuclear Medicine ·John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan G. Murphy, Scott Williams, Rodney J. Hicks, Michael S. Hofman Hit paper breakdown →	2018	339
3	High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours Journal of Medical Imaging and Radiation Oncology ·Michael S. Hofman, Grace Kong, Oliver Neels, Peter Eu, Emily Hong, Rodney J. Hicks	2012	201
4	Development and use of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for MRI Biomedical Imaging and Intervention Journal ·J Lodhia, Giovanni Mandarano, NJ Ferris, Peter Eu, SF Cowell	2010	160
5	Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression Clinical Genitourinary Cancer ·Louise Emmett, Megan Crumbaker, Bao Ho, Kathy Willowson, Peter Eu, Lalith Ratnayake, Richard J. Epstein, Ashley Blanksby, Lisa G. Horvath, Alex Guminski, Kate Mahon, Craig Gedye, Charlotte Yin, Phillip D. Stricker, Anthony M. Joshua	2018	126
6	Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system Cancer Imaging ·Jean‐Mathieu Beauregard, Michael S. Hofman, Jucilene Maria Pereira, Peter Eu, Rodney J. Hicks	2011	111
7	Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma Journal of Pediatric Hematology/Oncology ·Grace Kong, Michael S. Hofman, William K. Murray, Sharyn Wilson, Paul Wood, Peter Downie, Leanne Super, Annette Hogg, Peter Eu, Rodney J. Hicks	2015	96
8	⁶⁸Ga PET/CT Ventilation–Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy Journal of Nuclear Medicine ·Michael S. Hofman, Jean‐Mathieu Beauregard, Thomas W. Barber, Oliver Neels, Peter Eu, Rodney J. Hicks	2011	80
9	Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging ·Raghava Kashyap, Michael S. Hofman, Michael Michael, Grace Kong, Timothy Akhurst, Peter Eu, Diana Zannino, Rodney J. Hicks	2014	78
10	Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT) European Journal of Nuclear Medicine and Molecular Imaging ·Grace Kong, Matthew Thompson, Marnie Collins, Alan Herschtal, Michael S. Hofman, V. Johnston, Peter Eu, M. Michael, Rodney J. Hicks	2014	70
11	In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma Cancer Immunology Immunotherapy ·David Ritchie, Linda Mileshkin, Dominic Wall, Jacques Bartholeyns, Matthew Thompson, J. Coverdale, Eddie Lau, J. Wong, Peter Eu, Rodney J. Hicks, H. Miles Prince	2006	65
12	Alemtuzumab in the Treatment of Refractory Acute Rejection and Bronchiolitis Obliterans Syndrome After Human Lung Transplantation American Journal of Transplantation ·B. Diane Reams, Laura W. Musselwhite, David Zaas, Mark P. Steele, Stavros Garantziotis, Peter Eu, Laurie D. Snyder, Julia Curl, Song Lin, R. Duane Davis, Scott M. Palmer	2007	64
13	Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP Scientific Reports ·Carleen Cullinane, Kelly Waldeck, Laura Kirby, Buck E. Rogers, Peter Eu, Richard W. Tothill, Rodney J. Hicks	2020	63
14	Review on Production of 89Zr in a Medical Cyclotron for PET Radiopharmaceuticals Journal of Nuclear Medicine Technology ·Azahari Kasbollah, Peter Eu, Simon F. Cowell, Pradip Deb	2013	62
15	Quasi-Cubic Magnetite/Silica Core-Shell Nanoparticles as Enhanced MRI Contrast Agents for Cancer Imaging PLoS ONE ·Jos L. Campbell, Jyoti Arora, Simon F. Cowell, Ashish Garg, Peter Eu, Suresh K. Bhargava, Vipul Bansal	2011	57
16	Imaging of hypoxia with ¹⁸F‐FAZA PET in patients with locally advanced non‐small cell lung cancer treated with definitive chemoradiotherapy Journal of Medical Imaging and Radiation Oncology ·Mateya Trinkaus, Rob Blum, Danny Rischin, Jason Callahan, Mathias Bressel, Tatiana Segard, Peter Roselt, Peter Eu, David Binns, Michael MacManus, David Ball, Rodney J. Hicks	2013	56
17	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of ⁶⁸Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer Journal of Nuclear Medicine ·Michael S. Hofman, Peter Eu, Price Jackson, Emily Hong, David Binns, Amir Iravani, Declan G. Murphy, Catherine Mitchell, Shankar Siva, Rodney J. Hicks, Jennifer D. Young, Philip J. Blower, Gregory Mullen	2017	51
18	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging ·Grace Kong, Jason Callahan, Michael S. Hofman, David A. Pattison, Tim Akhurst, Michael Michael, Peter Eu, Rodney J. Hicks	2016	47
19	High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT European Journal of Nuclear Medicine and Molecular Imaging ·Jason Callahan, Michael S. Hofman, Shankar Siva, Tomas Kron, Michal Schneider, David Binns, Peter Eu, Rodney J. Hicks	2013	46
20	Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN) Journal of Nuclear Medicine ·Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Adam Hickey, Peter Eu, Martin R. Stockler, Andrew Martin, Anthony M. Joshua, Andrew Nguyen, Louise Emmett	2022	40

About Peter Eu

Peter Eu is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine, Oncology, Internal Medicine and Neurology, having authored 55 papers that have together received 3.1k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (24 papers), Prostate Cancer Treatment and Research (14 papers), Medical Imaging Techniques and Applications (13 papers), Neuroendocrine Tumor Research Advances (10 papers), Lung Cancer Research Studies (8 papers), Neuroblastoma Research and Treatments (7 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Nanoparticle-Based Drug Delivery (4 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.8k citations), Pulmonary and Respiratory Medicine (1.5k citations), Oncology (989 citations), Neurology (415 citations) and Radiation (204 citations). Peter Eu has collaborated with scholars based in Australia, United States and Canada. Frequent co-authors include Rodney J. Hicks, Michael S. Hofman, Grace Kong, Price Jackson, Amir Iravani, Tim Akhurst, Scott Williams, Declan G. Murphy, John Violet and Shahneen Sandhu. Their work appears in journals such as Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Journal of Clinical Oncology, Cancer Imaging and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact